News

Halozyme Therapeutics, Inc. and Antares Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per…
Read More...

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide,…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for…
Read More...

Pfizer Inc. and BioNTech SE announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the…
Read More...

aTyr Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, efzofitimod, for the…
Read More...

Halozyme Therapeutics, Inc. and Antares Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per…
Read More...

Astellas Pharma Inc. and Seagen Inc. announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally…
Read More...

GlaxoSmithKline plc and Sierra Oncology, Inc announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage…
Read More...

Juniper Biologics, a science-led healthcare company focused on researching, developing and commercializing novel therapies announced that it has gained the licensing rights to develop…
Read More...

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced that it has exercised its option to enter into an exclusive worldwide…
Read More...

Achilles Therapeutics plc a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the…
Read More...

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration…
Read More...

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform,…
Read More...

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today…
Read More...

SciRhom GmbH announced that it has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier…
Read More...

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update…
Read More...

Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers. Telix is pleased to announce that it has entered into a licence…
Read More...

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly…
Read More...

Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company, announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian…
Read More...

Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, announced a strategic manufacturing services agreement with National…
Read More...